Genmab, Global Agreement for HuMax-CD20 Receives Antitrust Clearance

| Source: Genmab A/S Genmab A/S 

The worldwide agreement to co-develop and commercialize HuMax-CD20 entered into between Genmab and GSK has received antitrust clearance.

Attachments

102668.pdf